Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Privigen 100 mg/ml solution for infusion, Gammanorm, 165 mg/ml, oplossing voor injectie, Octagam 10%, oplossing voor infusie, Nanogam 100 mg/ml oplossing voor infusie, Hizentra 200 mg/ml solution for subcutaneous injection, HyQvia 100 mg/ml solution for infusion for subcutaneous use, Cuvitru 200 mg/ml oplossing voor subcutane injectie, KIOVIG 100 mg/ml solution for infusion, CUTAQUIG 165 mg/mL, solution injectable, GAMMAGARD S/D 5,0 g, poeder en oplosmiddel voor oplossing voor infusie.
Disc Medicine
Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)
1 trial -
Prolastin 1000 mg, Pulver und Lösungsmittel zur Her- stellung einer Infusionslösung, Prolastin 5000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Prolastin 4000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
Instituto Grifols S.A.
Severe Alpha-1 Antitrypsin Deficiency (AATD)
1 trial -
Qarziba 4.5 mg/mL concentrate for solution for infusion
COLLEGIUM PHARMACEUTICAL, INC
Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.
1 trial -
RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE
Takeda
Active Chronic Pouchitis
1 trial -
RITUXIMAB , SODIUM CHLORIDE, Placebo for lenalidomide 25mg, PREDNISONE , MINJUVI 200 mg powder for concentrate for solution for infusion, PREDNISOLONE , LENALIDOMIDE, DOXORUBICIN , Placebo for lenalidomide 10mg, VINCRISTINE , LENALIDOMIDE, Placebo for lenalidomide 15mg, LENALIDOMIDE, CYCLOPHOSPHAMIDE
Incyte
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)
1 trial -
RO7047650, Tecentriq 1 200 mg concentrate for solution for infusion
Hoffmann-La Roche
Renal cell carcinoma (RCC)
1 trial -
RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D
Hoffmann-La Roche
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer
1 trial -
Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s
Incyte
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
1 trial -
Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion
Fondazione Telethon ETS
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT
1 trial -
Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion
AstraZeneca AB
Large B-cell Lymphoma
1 trial -
RoActemra 20 mg/mL concentrate for solution for infusion, Tofidence 20 mg/mL concentrate for solution for infusion, Avtozma 20 mg/mL concentrate for solution for infusion., SODIUM CHLORIDE, Tyenne 20 mg/ml concentrate for solution for infusion
Pari Pharma GmbH
Chondrocalcinosis
1 trial -
Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE
Hoffmann-La Roche
This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
1 trial -
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
1 trial -
SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.
Pari Pharma GmbH
Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.
1 trial -
SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile
Talion
Major Depressive Disorder (MDD)
1 trial -
SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile
Talion
Major Depressive Disorder (MDD)
1 trial -
SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB
AstraZeneca AB
Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)
1 trial -
SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion
Pari Pharma GmbH
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
1 trial -
SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets
Amgen
Colorectal Cancer (CRC)
1 trial -
SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
Saline (0.9%, sterile, for infusion)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pneumocystis Jiroveci Pneumonia
1 trial -
Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab
Biogen
Kidney Transplant Recipients with Late Antibody-Mediated Rejection
1 trial -
Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl
Sarepta Therapeutics
Duchenne Muscular Dystrophy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources